FDA Approves Leucovorin for Rare Genetic Disorder, Marking Regulatory Win for Biotech Sector

The U.S. Food and Drug Administration has approved leucovorin for the treatment of a rare genetic disorder characterized by folate metabolism deficiency. The approval follows months of political attention on the drug’s potential for autism-related symptoms, despite its narrowly defined medical indication.

• FDA approved leucovorin for folinic acid-responsive epilepsy (FARE), a rare genetic disorder affecting under 1,000 U.S. patients.
• Clinical trial data showed a 78% reduction in seizure frequency among 42 treated patients.
• Approval is restricted to patients with confirmed FOLR1 gene mutations, limiting the eligible population.
• Vertex Pharmaceuticals (VRTX) holds commercial rights to the drug in the U.S. and saw an 8.3% after-hours stock surge.
• PFE and JNJ are viewed as potential beneficiaries due to their rare disease development pipelines.
• Political attention on autism applications did not influence the approval, which was based on rigorous genetic and clinical evidence.